Business Context and Reporting Period
Company: MDB Capital Holdings, LLC (MDBH)
Reporting Period: Quarter ended June 30, 2024 (Q2 2024)
Business Overview: MDB is a holding company operating through two primary segments: (1) Broker Dealer & Intellectual Property Services (Public Ventures and PatentVest) and (2) Technology Development (Invizyne Technologies, a synthetic biology company). The company completed its IPO in September 2023 and is classified as a Smaller Reporting Company and Emerging Growth Company.
Key Financial Metrics (Six Months Ended June 30, 2024)
| Metric | Value |
|---|---|
| Total Operating Income | $1,628,061 |
| Net Operating Loss | $(13,071,909) |
| Net Loss (Consolidated) | $(12,415,192) |
| Net Loss Attributable to MDB | $(11,489,866) |
| Loss Per Share (Class A & B) | $(1.24) |
| Cash and Cash Equivalents | $17,523,769 |
| Working Capital | $24,928,197 |
| Debt | $0 (No drawdowns on $2M credit facility) |
| Stock-Based Compensation | $7,650,951 (Non-cash expense) |
Material Changes vs. Prior Period
- Revenue Decline: Total operating income decreased 72.2% year-over-year (from $5.85M to $1.63M). This was driven by a 69.2% drop in fee income and an 89.7% decrease in unrealized gains on investment securities compared to Q2 2023.
- Expense Surge: Total operating costs increased 228.7% year-over-year (from $4.47M to $14.70M). The primary driver was a 442.7% increase in compensation expenses, largely due to the recognition of restricted stock units (RSUs) and hiring for the technology segment.
- Profitability Shift: The company swung from a net income of $1.59M in the prior year period to a net loss of $11.49M attributable to MDB.
- Balance Sheet: Cash and cash equivalents increased 186.8% to $17.5M, while investment securities at amortized cost (U.S. Treasury Bills) decreased 79.6% as they were sold to fund operations and moved to money market accounts.
Guidance, Outlook, Risks, and Unusual Items
- Segment Performance: The Broker Dealer segment generated a net operating loss of $1.71M for the six months, while the Technology Development segment (Invizyne) reported a net operating loss of $2.34M. The Technology segment had zero operating income, down from $70,769 in the prior year, due to the absence of a one-off feasibility study.
- Grant Funding: Research and development costs for Invizyne are partially offset by government grants. Net R&D costs increased significantly due to a decrease in grant funding timing, though management expects this to fluctuate.
- Subsequent Event: On July 1, 2024, MDB formed "Minnesota One" with Mayo Foundation to develop pharmaceuticals. MDB holds a 67% stake and has agreed to invest up to $5 million over five years.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, due to material weaknesses in internal control over financial reporting. Remediation efforts are ongoing.
- Liquidity: The company maintains a $2.0 million revolving credit facility with no outstanding balance. Working capital increased to $24.9M, providing a buffer for operations.
Investor Verification Checklist
- Stock-Based Compensation Impact: Verify the sustainability of operations excluding the $7.65M non-cash stock-based compensation expense, which heavily inflated the reported net loss.
- Grant Reliability: Assess the stability of Invizyne's funding, as R&D costs are highly sensitive to the timing and amount of government grant reimbursements.
- Internal Control Remediation: Monitor the progress of remediation for the identified material weaknesses in financial reporting controls.
- Revenue Concentration: Evaluate the dependency on large, sporadic investment banking deals for fee income, as evidenced by the significant variance between 2023 and 2024.
- Minnesota One Investment: Review the terms and capital requirements of the new joint venture with Mayo Foundation to understand future cash outflow obligations.